Cell 2012;148:21327
Metoclopramide has traditionally been a first-line prokinetic therapy, but this agent should be administered at the lowest effective dose and for limited periods of time due to the real risk of adverse effects
Results To clarify the isoprenaline infarction/reinfarction and stable gastric pentadecapeptide BPC 157, we challenge the possibility that the stable gastric pentadecapeptide BPC 157, as a useful peptide therapy against isoprenaline myocardial infarction, as well as against isoprenaline myocardial reinfarction, should follow the activation of the collateral rescuing pathways seeable for the counteraction of the recently described occlusion-like syndrome, induced peripherally and centrally, that would also appear in the isoprenaline-treatedrats, being decisive for further full myocardial infarction development
Could this peptide have similar fat-related benefits in a broader population as well
First, lifestyle measures nutrition, movement, sleep, stress management and avoidance of harmful substances remain the foundation of long-term metabolic health, regardless of medication